Akademik Veri Yönetim Sistemi
2 nd INTERNATIONAL AND 27th NATIONAL PHARMACOLOGY CONGRESS, Antalya, Türkiye, 23 Kasım 2023, ss.261-262
Objectives: According to Global Cancer Observatory (GLOBOCAN) 2022 data, 19 million new cancer cases and 10 million
cancer-related deaths occurred worldwide. Prices of drugs can be a significant obstacle for patients to access cancer drugs.
The aim of this study is to evaluate access to cancer drugs through drug box sales data by modeling population growth, cancer
incidence and Fixed Euro Exchange (FEE) rate parameters used in drug pricing in Turkiye.
Materials-Methods: According to the Anatomical Therapeutic Chemical (ATC) classification "Antineoplastic agents (L01)"
group, box sales from warehouses to hospitals and pharmacies were obtained monthly data between 2003 and 2018 from
the IQVIA database. Box sales data classified according to diagnosis codes (ICD-10), reference or generic status. Consumption
of cancer drugs was examined over time with panel regression analysis, taking into account variables of population growth,
cancer incidence and FEE rate in drug pricing in Turkiye.
Results: The incidence of cancer in Turkiye was 189.6 in 2004 and 223.1 (per hundred thousand) in 2017. While there was a
167% increase in the real euro exchange rate, there was a 43.5% increase in the FEE rate. With the linear regression approach,
there is a negative relationship between the FEE rate and reference drug consumption data.
While there was a positive relationship between the population growth and box consumption, there was no significant
relationship between cancer incidence and box consumption data. In terms of generic drugs, there was a negative relationship
between FEE rate and population or cancer incidence variables. When evaluated according to ICD-10 codes; a positive
relationship was observed between box consumption of non-small cell lung cancer and each of the specified parameters. A
negative relationship was observed between box consumption of colon cancer, malignant melanoma, multiple myeloma or
leukemia diagnoses and the FEE rate.
Conclusions: According to panel regression analysis, FEE rate in drug pricing were observed as an important factor affecting
drug access, except for some diagnoses in our country.